BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8434965)

  • 1. [Increase in CDDP therapeutic index by lower concentration and longer infusion time--home chemotherapy for ovarian cancer].
    Chen JT; Tatsuki Y; Hirai Y; Hasumi K
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):265-70. PubMed ID: 8434965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H; Hayata T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
    Nishimura H; Yamada T; Hagio Y; Inoue T; Tsunawaki A; Yakushiji M; Kato T
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):938-43. PubMed ID: 6683483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
    Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
    Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
    Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
    Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
    Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
    Kawagoe K; Tsunoda H; Iijima S; Yokota H; Shigemitsu S
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):452-7. PubMed ID: 6538404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical results of repeated intraperitoneal administration of CDDP in patients with ovarian cancer].
    Usui N; Suzuki M; Furugen Y; Fuchiwaki T; Nagasawa I; Yamamoto T; Takeuchi H; Kuwabara Y
    Gan To Kagaku Ryoho; 1993 Aug; 20(10):1327-31. PubMed ID: 8346931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer].
    Kobayashi H; Maeda M; Hayata T; Kawashima Y
    Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):829-36. PubMed ID: 3204307
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
    Ehrlich CE; Einhorn L; Williams SD; Morgan J
    Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
    [No Abstract]   [Full Text] [Related]  

  • 17. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
    Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
    J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low-dose CDDP and 5-FU for head and neck cancer patients].
    Fujii M; Kanke M; Tomita T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.